Modulation of GABA A receptors by benzodiazepines (BZDs) is believed to involve two distinct steps: a recognition step in which BZDs bind and a conformational transition step in which the affinity of the receptor for GABA changes. Previously, using ␥ 2 /␣ 1 chimeric subunits (), we demonstrated that although the N-terminal 167 ␥ 2 amino acid residues confer high-affinity BZD binding, other ␥ 2 domains couple BZD binding to potentiation of the GABA-mediated Cl Ϫ current (I GABA ). To determine which ␥ 2 regions couple binding to potentiation, we generated s with longer N-terminal ␥ 2 segments for voltage-clamp experiments in Xenopus oocytes. Chimeras containing greater than the N-terminal 167 ␥ 2 residues showed incremental gains in maximal potentiation for diazepam enhancement of I GABA . Residues in ␥ 2 199-236, ␥ 2 224-236 (pre-M1), and particularly ␥ 2 257-297 (M2 and surrounding loops) are important for BZD potentiation.
Modulation of GABA A receptors by benzodiazepines (BZDs) is believed to involve two distinct steps: a recognition step in which BZDs bind and a conformational transition step in which the affinity of the receptor for GABA changes. Previously, using ␥ 2 /␣ 1 chimeric subunits (), we demonstrated that although the N-terminal 167 ␥ 2 amino acid residues confer high-affinity BZD binding, other ␥ 2 domains couple BZD binding to potentiation of the GABA-mediated Cl Ϫ current (I GABA ). To determine which ␥ 2 regions couple binding to potentiation, we generated s with longer N-terminal ␥ 2 segments for voltage-clamp experiments in Xenopus oocytes. Chimeras containing greater than the N-terminal 167 ␥ 2 residues showed incremental gains in maximal potentiation for diazepam enhancement of I GABA . Residues in ␥ 2 199-236, ␥ 2 224-236 (pre-M1), and particularly ␥ 2 257-297 (M2 and surrounding loops) are important for BZD potentiation.
For several positive BZD modulators tested, the same regions restored potentiation of I GABA . In contrast, ␤-carboline inverseagonism was unaltered in chimeric receptors, suggesting that structural determinants for positive and negative BZD allosteric modulation are different. Dissection of the ␥ 2 257-297 domain revealed that three residues in concert, ␥ 2 T281, ␥ 2 I282 (M2 channel vestibule), and ␥ 2 S291 (M2-M3 loop) are necessary to impart full BZD potentiation to chimeric receptors. Thus, these residues participate in coupling distant BZD-binding events to conformational changes in the GABA A receptor. The location of these novel residues provides insight into the mechanisms underlying allosteric coupling for other members of the ligandgated ion channel superfamily.
Key words: GABA; GABA A receptor; benzodiazepines; benzodiazepine-binding site; allosteric coupling; chimeric subunits; mutagenesis; inverse agonist; positive modulation; ␥ subunit; ␣ subunit; M2 domain; M2-M3 loop; Xenopus oocytes GABA A receptors are the major inhibitory neurotransmitter receptors in the mammalian brain and are members of a ligandgated ion channel (LGIC) superfamily (Ortells and L unt, 1995) , which also includes receptors for acetylcholine, glycine, and serotonin. The GABA A receptor gene family comprises several different classes and subtypes of receptor subunits including 6␣, 4␤, 3␥, 1␦, 1⑀, and 1 (Barnard et al., 1998) . GABA A receptors are pentameric proteins containing an integral chloride-selective channel with specific binding sites for GABA, benzodiazepines (BZDs), barbiturates, and steroids (Smith and Olsen, 1995) . BZDs, clinically used for their anxiolytic and antiepileptic actions, exert their therapeutic effects by allosteric modulation of GABA A receptors (Sieghart, 1995) . Positive BZ D modulators increase the opening frequency of the C l Ϫ channel in the presence of GABA, whereas negative BZ D modulators (e.g., ␤-carbolines) decrease the opening frequency (Rogers et al., 1994) . Because the therapeutic clinical value of these drugs depends on their ability to exert positive modulation on I GABA , we were interested in identifying the structural determinants underlying BZD efficacy in potentiating GABA-gated currents.
Evidence suggests that both the ␣ and ␥ subunits play critical roles in BZD binding and potentiation. Using the agonist-binding site of the nicotinic ACh receptor as an archetype for pentameric LGIC receptors (Czajkowski et al., 1993) , the BZD-binding site of the GABA A receptor has been modeled with the ␥ subunit apposed to an ␣ subunit, and both subunits contributing to the binding site at the interface (Galzi and Changeux, 1994; Smith and Olsen, 1995) . Although several studies have begun to identify amino acids in both ␥ and ␣ subunits involved in BZD binding (for review, see Sigel and Buhr, 1997) , little is known about the structural components involved in coupling BZD binding to BZD potentiation of GABA-gated current (I GABA ).
Our previous studies using ␥ 2 /␣ 1 chimeric subunits demonstrated that chimeras () containing the N-terminal 161 amino acid residues of ␥ 2 exhibit wild-type binding but drastically impaired potentiation of I GABA by BZDs (Boileau et al., 1998) . To further delineate the regions unique to the ␥ 2 subunit that confer BZD potentiation, we generated additional ␥ 2 /␣ 1 chimeras, expanding the length of the N-terminal ␥ 2 portion and reducing the ␣ 1 C-terminal portion (Fig. 1) . Two main regions of the ␥ subunit, ␥ 2 224 -236 and ␥ 2 257-297, improve the allosteric coupling of BZD binding to potentiation of I GABA . The largest gain in potentiation is conferred by the ␥ 2 257-297 region, which surrounds and includes the M2 transmembrane segment. Further investigation revealed that a triplet set of residues, ␥ 2 T281, I282, and S291 underlie this function of the ␥ 2 subunit. Unlike positive modulatory BZD compounds, the negative modulator 3-carbomethoxy-4-ethyl-6,7-dimethoxy-␤-carboline (DMCM) exhibits f ull wild-type inhibition for all chimeric receptors.
MATERIALS AND METHODS
Molecular cloning. Chimeras are named for the last ␥ 2 amino acid residue before the crossover with ␣ 1 in the mature rat protein sequence. Thus, numbering for and ␥ 2 subunits is identical. For chimeras used in this study (Fig. 1) , the ␥ 2 and ␣ 1 amino acid residues at the crossovers are "␥D161/␣A149"(161), "␥L167/␣K155" (167), "␥L198/␣N188" (198), "␥M223/␣T213" (223), "␥F236/␣V226" (236), "␥W256/␣L246" (256), and "␥D297/␣W287" (297). 161 and 167 were generated by a targeted random chimera production method (Boileau et al., 1998) . All others (Fig. 1 A) were produced by recombinant PCR using overlapping complementary oligonucleotides designed to create a ␥/␣ crossover at the desired amino acid junction. Using a ␥ 2 sense oligonucleotide and an antisense ␥/␣ junction oligonucleotide with ␥ 2 cDNA as a template, upstream PCR fragments with ␥ 2 5Ј and an ␣ 1 3Ј overhang were generated. Simultaneously, using a sense junction oligonucleotide and an ␣ 1 antisense oligonucleotide with ␣ 1 cDNA as template, downstream PCR fragments with ␥ 2 5Ј overhang and ␣ 1 3Ј sequences were also prepared in separate PCR reactions. Upstream and downstream PCR fragments were then combined and amplified to create ␥/␣ DNA cassette fragments that were subcloned into 167 cDNA using AflII and NcoI, thus replacing the cassette region of 167 with the new chimeric junction sequences.
Mutant subunit fragments were generated using the same recombinant PCR method and subcloned into the background of the 236 subunit to generate different combinations of mutants (Fig. 1 B) . Single and multiple mutants were named according to the ␣ 1 to ␥ 2 substitutions made in 236. For example, the "236-RES3 K DA" mutant is 236 with ␣ 1 Arg-GluSer (RES) residues replaced by the aligned ␥ 2 sequence at positions 259 -261, Lys-Asp-Ala (K DA). The "236-A291S" mutant replaces ␣ 1 Ala with ␥ 2 Ser291 in 236; the "236-I281T ϩ A291S" mutant is 236 with an I281T and an A291S mutation. The chimeric and mutant subunits were subcloned in pGH19 vector (Liman et al., 1992; Robertson et al., 1996) for expression in Xenopus oocytes. All chimeras were verified by restriction digest and double-stranded DNA sequencing using standard techniques (Sambrook et al., 1989) .
E xpression of rat GA BA A receptors in Xenopus ooc ytes. C apped cRNA coding for the wild-type and chimeric subunits was synthesized by in vitro transcription from NheI-linearized cDNA template in pGH19 using the mMessage mMachine T7 kit (Ambion). Oocytes from Xenopus laevis were prepared as previously described (Boileau et al., 1998) and injected with 28 nl of mRNA (10 -200 pg /nl /subunit) mixed in a ratio of 1:1 (␣:␤), or 1:1:Ն20 (␣:␤:␥ or ␣:␤:). E xcess molar ratios of ␥ or cRNA were injected to ensure expression of these subunits in the receptor complex (Boileau et al., 1998) . Oocytes were stored at 17-19°C in recording solution supplemented with 100 g /ml gentamycin and 100 g /ml BSA, and were used for electrophysiological experiments 2-14 d after injection. Total amount of cRNA was scaled to yield maximal GABA-induced currents of ϳ3-8 A for ␣ 1 ␤ 2 ␥ 2 and ␣ 1 ␤ 2 . cRNA concentrations were calculated by UV absorption and corroborated by comparison to RNA standards on 1.5% agarose gels.
Voltage-clamp anal ysis. Oocytes under two-electrode voltage-clamp (V hold ϭ Ϫ80 mV) were perf used continuously with N D96 recording solution containing (in mM) 96 NaCl, 2 KCl, 1.8 CaCl 2 , 1 MgC l 2 , and 5 H EPES, pH 7.4 at a rate of 5 ml /min. In general, drugs and reagents were dissolved in N D96. Stock drug solutions (1000 -10,000ϫ) were made in dimethylsulfoxide. No differences in currents were observed with the vehicle. Maximal current (ϳ3-8 A) for all receptors was achieved with 10 mM GABA. For some chimeras and mutants, GABA EC 50 was estimated by examining the ratio of response to 1 M versus 10 mM GABA. GABA (1 M) elicits currents corresponding to EC 5 for both ␣ 1 ␤ 2 (range, EC 2-7 ) and ␣ 1 ␤ 2 ␥ 2 (EC 4.8 Ϯ 1.7 ) receptors. Using a standard Hill equation to model the GABA dose responses and the determined 1 M/10 mM GABA current ratio, we calculate that the chimeric and mutant receptors show no more than a twofold shift in GABA EC 50 from wild-type receptors (EC 50 ϭ 12 M). Greater than twofold shifts are detectable in our assay.
BZ D potentiation or ␤-carboline inhibition I GABA were recorded at 1 M GABA (EC 5 ). Potentiation is defined as (I GABA ϩ DRUG /I GABA ) Ϫ 1), where I GABA ϩ DRUG is the current response in the presence of the drug tested, and I GABA is the control GABA-induced current. For single concentration experiments, BZ D site ligands were tested at concentrations eliciting maximal effects on I GABA in wild-type ␣ 1 ␤ 2 ␥ 2 receptors. If differences in potentiation for mutant receptors were caused entirely by a shift in GABA affinity, the Hill equation predicts that a sixfold shift in GABA affinity, and only to the left, would be required to account for a 50% reduction in maximal potentiation. This would result in a 1 M/10 mM GABA ratio corresponding to EC 27-32 (Hill coefficient varied from 1 to 2), well out of our observed range. Standard two-electrode voltageclamp recording was performed using a GeneC lamp 500 (Axon Instruments, Foster C ity, CA) interfaced to a computer with an I T-16 A / D device (Instrutech). Electrodes were filled with 3 M KC l and had a resistance of 0.5-1.5 M⍀. Data acquisition and analysis were performed using AxoData, AxoGraph (Axon Instruments), and Prism software (Graphpad). Statistical comparisons of potentiation data employed one-way ANOVA with Dunnet and T ukey post-tests for multiple independent samples using Prism software.
RESULTS
Regions of the ␥ 2 subunit responsible for BZ D binding can be separated from domains required for coupling BZ D binding to potentiation of I GABA (Boileau et al., 1998) . This "uncoupling" of high-affinity BZ D binding and potentiation is apparent in the ␥/␣ chimera 161, which binds BZ Ds with wild-type affinity when expressed with wild-type ␣ 1 and ␤ 2 subunits, but displays drastically impaired diazepam modulation of I GABA . In an effort to identif y regions of the ␥ 2 subunit required for f ull BZD potentiation, several additional chimeras (Fig. 1 A) were constructed with longer ␥ 2 N-terminal domains. Chimeras used here, named for the ␥ 2 amino acid where the crossovers occur, are 161, 167, 198, 223, 236, 256 , and 297 (see Materials and Methods). These chimeras were expressed in Xenopus oocytes and screened by two-electrode voltage clamp to test for restoration of allosteric modulation of I GABA with several structurally diverse BZDbinding site ligands. The expression, BZ D radioligand binding, and diazepam modulation of GABA-gated currents for ␣ 1 ␤ 2 161 and ␣ 1 ␤ 2 167 receptors have been described previously (Boileau et al., 1998) .
Different domains alter BZD EC 50 and potentiation
Chimeric cRNA was coinjected with wild-type ␣ 1 and ␤ 2 subunit cRNA into oocytes and tested for diazepam potentiation of I GABA with 1 M GABA. This concentration corresponded to EC 5 for GABA for both wild-type and chimeric receptors. Both maximal potentiation and EC 50 for diazepam modulation of I GABA were measured. Dose -response curves and traces for diazepam potentiation of the GABA response for selected chimera-containing and wild-type receptors are depicted in Figure 2 . At concentrations Ͼ1 M diazepam, potentiation of wildtype receptors begins to depress (Fig. 2 , dashed line; Amin et al., 1997) . The decrease may be attributable to channel block and/or BZD blockage of the GABA-binding site. Receptors containing 161 and 167 exhibited low potentiation, whereas chimeras with increasingly longer N-terminal ␥ 2 segments exhibited incremental gains in maximal potentiation (Table 1, Fig. 2 ). Full potentiation was restored with 297, which contains ␥ 2 residues up to the beginning of the M3 transmembrane domain. For maximal potentiation, data from chimeric and wild-type receptors yielded the series
Differences in EC 50 for diazepam potentiation of I GABA between chimeric and wild-type receptors were also measured ( Fig.  2, inset (Fig. 2, inset) . It was also noted that 198 displays unusually fast desensitization to application of either GABA or GABA plus diazepam. The reason for this is unclear, and was not pursued. Interestingly, although the diazepam EC 50 for ␣ 1 ␤ 2 256 receptors was similar to wild-type ␣ 1 ␤ 2 ␥ 2 receptors, the maximal potentiation was reduced by ϳ60% compared to wild-type receptors ( Fig. 2; see Fig. 4 ). The most significant gain of potentiation occurred between 256 and 297 (Fig. 1) ; ␣ 1 ␤ 2 297 receptors exhibit potentiation and EC 50 for diazepam indistinguishable from wild-type receptors.
Positive BZD modulators use the ␥257-297 domain
To explore whether potentiation or inhibition by other drugs acting at the BZD site would require similar regions of the ␥ 2 subunit, the chimeras were tested with several different BZD- 
, and ␣ 1 ␤ 2 297 (E) exposed to 1 M GABA plus diazepam (DZ) by the response to 1 M GABA alone. Data were fitted to a curve described by the equation
where Ma x is the maximal potentiation, Min is the potentiation at the lowest drug concentration tested, X is the logarithm of diazepam concentration, EC 50 is the halfmaximal potentiation response, and n H is the Hill coefficient. Data points represent mean potentiation from four or more cells from two or more batches of oocytes. Error bars indicate SD. The parameters from the curve fits are presented in Table 1 . Inset, A plot of the same data after normalizing to the maximum diazepam potentiation for each receptor.
binding site ligands. Surprisingly, the ␤-carboline DMCM, an inverse agonist at the BZ D site, inhibited I GABA in all chimeric receptors to the same extent as wild-type ␣ 1 ␤ 2 ␥ 2 receptors (Fig.  3) . In contrast, the positive modulatory BZ D site ligands tested showed significant differences in potentiation between chimeric receptors (Fig. 4, Table 2 ). The differences between chimeric receptors for positive modulation could be caused by inefficient expression of the chimera in a receptor complex, yielding a mixture of ␣ 1 ␤ 2 and ␣ 1 ␤ 2 receptors that would appear to have reduced potentiation. However, the observation that each chimera responds to DMC M akin to ␣ 1 ␤ 2 ␥ 2 receptors, and not ␣ 1 ␤ 2 receptors, allays this concern.
Classical 1,4-benzodiazepines such as diazepam and watersoluble flurazepam exhibited similar increments in potentiation of I GABA in chimeras with increasingly larger N-terminal segments (Fig. 4 A) . The strong positive modulators midazolam (a triazolobenzodiazepine, Fig. 4 B) and zolpidem (an imidazopyridine, Fig. 4C ), and the partial agonist CL218,872 (a triazolopyridazine, Fig. 4 D) also showed increments in potentiation from 167 to 297, indicating a common pattern of residues required for positive BZD allosteric modulation. Table 2 summarizes the effects of various BZD site ligands on the potentiation of I GABA for chimeric receptors compared to wild-type ␣ 1 ␤ 2 ␥ 2 receptors. For all positive modulators tested, a correlation between recovery of potentiation and length of the chimeric ␥ 2 sequence emerges. Small increases in potentiation are observed between 167 and 223 (ϳ10 -15%), and between 223 and 236 (ϳ10 -25%) for all of the positive modulators tested. Whether a significant recovery of potentiation occurred between 167 and 198 or between 198 and 223 depended on the drug tested. The largest increases in potentiation (50 -60%) for all of the positive modulatory BZDs tested occurred between 256 and 297, indicating that amino acid residues surrounding and/or including M2 are required for full potentiation of I GABA by these drugs.
In addition, we tested the activity of the imidazobenzodiazepine antagonist Ro15-1788 (flumazenil; Fig. 4 B) in wild-type and chimera-containing receptors. Ro15-1788 (1 M) was effective at blocking the midazolam-induced (1 M) potentiation of I GABA in all chimeric receptors (Fig. 4 B, hatched bars) . At micromolar concentrations, Ro15-1788 acts as a weak positive modulator of GABA activation (Fig. 4 B, open bars; Mihic et al., 1997) . The pattern of potentiation in wild-type and chimeric receptors was similar to that seen for other positive modulators. After subtracting out the minor background Ro15-1788-induced potentiation, the midazolam-induced potentiation is inhibited by Ro15-1788 to the same extent for wild-type and all chimeric receptors (91.5 Ϯ 3.7%).
Mutations conferring positive modulation of I GABA
Because the largest gain in BZD potentiation is mediated by the ␥ 2 I257-D297 domain, we focused on identifying the amino acid residue or residues in this region that contribute to BZD modulation of I GABA . To determine whether ␣ 1 ␤ 2 236 receptors are altered in their ability to bind BZDs, we performed radioligandbinding assays. The K D for [ 3 H]flunitrazepam binding in ␣ 1 ␤ 2 236 receptors (3 Ϯ 1 nM; n ϭ 2) was similar to the values obtained for ␣ 1 ␤ 2 161 (11.3 Ϯ 1.7 nM) and ␣ 1 ␤ 2 ␥ 2 (9.9 Ϯ 0.8 nM; Boileau et al., 1998) . Several mutants were constructed in a 236 background, corresponding to nonidentical residues between ␥ 2 and ␣ 1 in the M1-M2 loop, the M2 transmembrane domain, and the M2-M3 loop (Fig. 1 B) . The first set of such mutants with ␣ 1 amino acid residues substituted to the homologous ␥ 2 residues were 236-RES3 KDA (Fig. 1 B, box a) , 236-RES3 KDA ϩ NAA3 KSV (box a ϩ box d), 236-VFGV3 SLGI (box b), 236-VFGV3 SLGI ϩ NAA3 KSV (box b ϩ box d), 236-IS3 TI (box c), and 236-IS3 TI ϩ AA3 SV (box c ϩ box e). Of these, only 236-IS3 TI ϩ AA3 SV (box c ϩ box e) exhibited full potentiation of I GABA by diazepam. All single-, double-, and triple-mutant combinations of the substitutions present in 236-IS3 TI ϩ AA3 SV (box c ϩ box e) were generated and tested with 1 M diazepam for potentiation of I GABA (Fig. 5 ). Of these, only the triple mutant combination 236-IS3 TI ϩ A291S (Fig.  1 B, depicted in Figure 5 are significantly different ( p Ͻ 0.01) from those for 297 except for the quadruple mutant 236-IS3 TI ϩ AA3 SV (box c ϩ box e) and the triple mutant 236-IS3 TI ϩ A291S. Diazepam dose -response curves for the components of 236-IS3 TI ϩ A291S, namely 236-IS3 TI, 236-A291S and the other two double mutants 236-I281T ϩ A291S and 236-S282I ϩ A291S demonstrate that all three mutations are necessary for full potentiation for diazepam (Fig. 6 ). Summary data for maximal potentiation and EC 50 values are shown in Table 1 . Although 236-A291S alone did restore some of the potentiation to 236, it is still significantly less than for 297 ( p Ͻ 0.01). The triple mutant also exhibited wild-type maximal potentiation for other BZD-positive modulators (Fig. 4, Table 2 ).
DISCUSSION
We previously reported that chimeric subunits with ␥ 2 sequence in the first 161 amino acid residues and ␣ 1 sequence in the remainder exhibit high-affinity BZ D binding, but impaired BZD modulation of I GABA (Boileau et al., 1998) . Efficient coupling of BZD binding to potentiation of I GABA is therefore mediated, at least in part, by ␥ 2 amino acid residues that are not directly involved in the binding of BZDs. In this study, we identified two novel ␥ 2 regions, ␥ 2 224 -236 (pre-M1) and ␥ 2 257-297 (M2 and surrounding loops) that are necessary for full restoration of coupling between high-affinity BZD binding and full BZD potentiation of I GABA by several disparate BZD positive allosteric modulators (Figs. 2, 4) . In addition, a threefold shift in EC 50 is observed between ␣ 1 ␤ 2 198 and ␣ 1 ␤ 2 223 receptors (Table 1) . This change in diazepam EC 50 may account for some or all of the increased potentiation observed in ␣ 1 ␤ 2 223 receptors as compared to ␣ 1 ␤ 2 167 receptors (Figs. 2, 4) .
For all the BZD positive allosteric modulators tested, the largest recovery in BZD potentiation of I GABA (50 -60%) is conferred by one or more ␥ 2 residues in and/or surrounding the M2 region between 256 and 297. For this region, a change in diazepam EC 50 cannot explain the complete restoration in the ability of diazepam to potentiate I GABA in ␣ 1 ␤ 2 297 receptors as compared to ␣ 1 ␤ 2 256 receptors because the diazepam EC 50 values for ␣ 1 ␤ 2 297 and ␣ 1 ␤ 2 256 receptors are not significantly different from each other or wild-type receptors (Table 1 ). The differences in levels of potentiation for chimeric receptors are also not caused by inefficient expression of the chimeric subunit, as evidenced by the equivalence of DMC M inhibition of I GABA for each chimeric receptor and ␣ 1 ␤ 2 ␥ 2 receptors (Fig. 3) . Thus, DMC M inhibition of I GABA serves as a usef ul benchmark and control for chimeric insertion into the receptor complex. Finally, the differences in potentiation are not attributable to differences in GABA dose responses. Previously, we established that ␣ 1 ␤ 2 161 and ␣ 1 ␤ 2 167 receptors have EC 50 values for GABA similar to ␣ 1 ␤ 2 ␥ 2 and ␣ 1 ␤ 2 receptors (Boileau et al., 1998) . In addition, we have calculated that the EC 50 values for all of the chimeric receptors are shifted by less than twofold compared to wild-type receptors (see Materials and Methods), which could not alone account for the decrease in maximal potentiation observed. Thus, we conclude that the ␥ 2 257-297 region contains structural determinants required for coupling BZD binding to BZD potentiation of I GABA .
Because DMCM inhibits ␣ 1 ␤ 2 167 receptors to a similar extent as wild-type ␣ 1 ␤ 2 ␥ 2 receptors (Fig. 3) , negative modulation of the GABA-gated current by ␤-carboline-binding to the BZD site must be transduced through different structural elements, i.e., using ␥ 2 residues located within the first 167 amino acid residues, with or without downstream ␥ 2 residues that are conserved in the ␣ 1 and ␥ 2 subunits. Because we are comparing ␣ to ␥ subunits for differences in BZD function, we cannot detect amino acid residues important for processes that are conserved between the two subunit subtypes.
The specific residues in the ␥ 2 257-297 region that underlie BZD potentiation of I GABA were identified. Of the twelve nonidentical residues between 256 and 297, the residues ␥ 2 T281, I282, and S291 are, in combination, necessary to confer wild-type potentiation of I GABA by positive BZD modulators (Figs. 4 -6 ). Although we cannot rule out the possibility that these mutations somehow serve to relieve a conformational dysfunction in the structure of the 236 subunit and do not play a direct role in BZD actions, we think this unlikely. Wild-type responses to DMCM and equivalent values for competitive displacement by Ro15-1788 for all the chimeric receptors suggest that the overall structures of the chimeras are not severely disrupted. Equilibrium binding values for [
3 H]flunitrazepam to ␣ 1 ␤ 2 161, ␣ 1 ␤ 2 167, and ␣ 1 ␤ 2 236 receptors were similar to wild-type receptors, indicating that the BZD-binding site is intact. Further support for our conclusion that ␥ 2 T281, I282 and S291 are compulsory ␥ 2 ele- ments for BZ D activity derives from the fact that all three residues are conserved in all known ␥ subunits cloned from various species but vary in other subunit subtypes. These identified residues, however, are not the sole ␥ 2 determinants controlling BZ D potentiation. C ertainly other ␥ 2 amino acid residues also play a role, particularly residues in the pre-M1 regions (e.g., ␥ 2 224 -236), which have yet to be identified, and /or amino acid residues that are conserved between the ␥ and ␣ subunits. Alterations in the ability of positive BZ D modulators to potentiate I GABA can arise from several possible sources, including alterations at the BZ D-binding site (Colquhoun, 1998) , disruptions of the coupling (transduction of BZ D binding to potentiation) machinery, and /or modifications of the ion channel pore itself. An example of a mutation that alters BZ D "efficacy" of several BZ D ligands is the ␥ 2 subunit mutation T142S (Mihic et al., 1994) ; both a competitive antagonist at the BZ D-binding site (Ro15-1788) and a weak negative modulator (Ro15-4513) take on the character of weak positive modulators. Because we previously demonstrated that high-affinity BZ D binding is localized to the N-terminal 161 ␥ 2 amino acid residues (Boileau et al., 1998) , the novel regions and residues identified in this study control BZD potentiation by influencing the coupling machinery and/or the ion channel pore itself rather than the BZD-binding site. For the chimeric receptors described in this study, strong positive BZD modulators behave like weak modulators or BZD antagonists. Additionally, we observe that ␣ 1 ␤ 2 161, ␣ 1 ␤ 2 167, and ␣ 1 ␤ 2 236 receptors exhibit wild-type, high-affinity radioligand binding. Together, these observations suggest that we are measuring disruptions in coupling rather than binding. Because ␥ 2 T281 and I282 are likely to line the water-accessible surface of the Cl Ϫ channel based on homology with the ␣ 1 subunit (Xu and Akabas, 1996) , it is tempting to speculate that this region controls BZD potentiation by affecting the ion channel. These ␥ 2 residues may influence ion channel gating, possibly facilitating channel opening by GABA when BZDs are present.
Structurally, allosteric coupling between GABA and BZDbinding sites could occur exclusively in the N-terminal extracellular domains of the receptor, from one binding site to the other. The Monod-Wyman-Changeux allosteric model predicts that ligand-binding events cause allosteric transitions that change the state of the receptor, which result in changes in the binding sites (Monod et al., 1965) . Our chimeric receptors have either weakened or deleted allosteric transitions that are restored by ␥ 2 segments distant from the presumed binding sites, and in particular by the combination of the channel-lining residues ␥ 2 T281 and I282 coupled with the M2-M3 loop residue ␥ 2 S291. Thus, allosteric coupling between the GABA and BZD-binding sites requires transduction through transmembrane or intracellular regions and then back out to the extracellular binding regions, subsequently affecting the kinetics of GABA binding at one or both cooperative GABA-binding sites.
Our results demonstrate that two M2 residues (␥ 2 T281, I282) and a M2-M3 extracellular loop residue (␥ 2 S291) are required for full, wild-type BZD potentiation of I GABA by a variety of BZD ligands. It is interesting that these ␥ 2 residues map to corresponding regions as residues in other GABA A receptor subunits and the homologous glycine receptor believed to be involved in "direct" channel gating by agonists. In the GABA A receptor, when the M2 central leucine is substituted with threonine in the human ␤ 1 subunit, GABA activation is abolished, even though binding with the GABA agonist [ 3 H]muscimol is unaltered (Tierney et al., 1996) . In the glycine receptor, mutation of ␣ 1 R271 (in the M2-M3 loop) to leucine or glutamine converts glycinergic agonists ␤-alanine and taurine from agonists to competitive antagonists for glycine (Rajendra et al., 1995) . Our results that residues in M2 and the M2-M3 loop are necessary for coupling BZD binding to BZD potentiation suggests that not only are the BZD and GABA-binding sites structurally conserved (Olsen et al., 1996) , but the regions of the receptor involved in the coupling of binding to their functional effects are also conserved. We speculate that the BZD-binding site may in reality be a very low-affinity GABA-binding site that over evolutionary time has acquired the ability to bind BZDs and when the ␥ 2 M2 region is present, BZDs may act as coagonists and increase channel opening frequency.
Mutations within the M2 region and surrounding loops in the GABA A receptor also affect the actions of other GABA A receptor modulators. Mutations in two specific M2 amino acid residues, ␣ 1 S267 or the aligned ␤ 1 S265, affect the ability of ethanol, enflurane, etomidate, loreclezole, and furosemide to modulate the GABA A receptor (Wingrove et al., 1994; Belelli et al., 1997; Mihic et al., 1997; Thompson et al., 1999) . Both of these residues align with ␥ 2 S280 (Fig. 1 B) . The position of these M2 residues relative to ␥ 2 T281 and I282 identified in this study suggest that A potentiation response ratio was determined by dividing the peak current for ␣ 1 ␤ 2 297 (E), ␣ 1 ␤ 2 236-IS3 TI ϩ A291S (OE), ␣ 1 ␤ 2 236-A291S (), ␣ 1 ␤ 2 236-IS3 TI (f), ␣ 1 ␤ 2 236-I281T ϩ A291S (᭛), ␣ 1 ␤ 2 236-S282I ϩ A291S (F), and ␣ 1 ␤ 2 236 (Ⅺ) exposed to 1 M GABA plus diazepam (DZ) by the response to 1 M GABA alone. Data were fitted to a curve described by the equation Y ϭ Min ϩ (Ma x Ϫ Min)/(1 ϩ 10 ((L ogEC50 Ϫ X)⅐nH ) ), where Max is the maximal potentiation, Min is the potentiation at the lowest drug concentration tested, X is the logarithm of diazepam concentration, EC 50 is the half-maximal potentiation response, and n H is the Hill coefficient. Data points represent mean potentiation from six or more cells from two or more batches of oocytes. Error bars indicate SD. The parameters from the curve fits are presented in Table 1. this region of M2 may not contain the binding site or sites for anesthetics and other related compounds, but instead may act as a common pathway for mediating the coupling between binding and the f unctional effects of these drugs. Mutations in either M2 or the M2-M3 loop in the glycine receptor also alter the efficacy of modulators and agonists (Rajendra et al., 1995; Lynch et al., 1997) . Thus, for LGIC receptors we hypothesize that the extracellular end of the channel and the nearby M2-M3 extracellular loop are transduction domains that help couple distant ligandbinding events to the channel gate.
